GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (LTS:0QIU) » Definitions » PB Ratio

Novo Nordisk A/S (LTS:0QIU) PB Ratio : 35.92 (As of Apr. 26, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Novo Nordisk A/S PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-26), Novo Nordisk A/S's share price is kr858.65. Novo Nordisk A/S's Book Value per Share for the quarter that ended in Dec. 2023 was kr23.90. Hence, Novo Nordisk A/S's PB Ratio of today is 35.92.

Warning Sign:

Novo Nordisk A/S stock PB Ratio (=36.76) is close to 10-year high of 37.86

The historical rank and industry rank for Novo Nordisk A/S's PB Ratio or its related term are showing as below:

LTS:0QIU' s PB Ratio Range Over the Past 10 Years
Min: 12.83   Med: 18.33   Max: 37.86
Current: 36.76

During the past 13 years, Novo Nordisk A/S's highest PB Ratio was 37.86. The lowest was 12.83. And the median was 18.33.

LTS:0QIU's PB Ratio is ranked worse than
97.94% of 1311 companies
in the Biotechnology industry
Industry Median: 2.37 vs LTS:0QIU: 36.76

During the past 12 months, Novo Nordisk A/S's average Book Value Per Share Growth Rate was 28.80% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 21.10% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 17.10% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 11.30% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Novo Nordisk A/S was 21.10% per year. The lowest was -2.30% per year. And the median was 7.90% per year.

Back to Basics: PB Ratio


Novo Nordisk A/S PB Ratio Historical Data

The historical data trend for Novo Nordisk A/S's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S PB Ratio Chart

Novo Nordisk A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.28 15.95 23.70 25.29 29.16

Novo Nordisk A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.29 30.44 27.10 31.53 29.16

Competitive Comparison of Novo Nordisk A/S's PB Ratio

For the Biotechnology subindustry, Novo Nordisk A/S's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk A/S's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's PB Ratio distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's PB Ratio falls into.



Novo Nordisk A/S PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Novo Nordisk A/S's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=858.65/23.902
=35.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Novo Nordisk A/S  (LTS:0QIU) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Novo Nordisk A/S PB Ratio Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk A/S (LTS:0QIU) Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, DK-2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk A/S (LTS:0QIU) Headlines

No Headlines